Pulmatrix, Inc. PULM
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
Day range unavailable
- YTD
- -37.22%
- 1 year
- -71.66%
- Open
- —
- Prev close
- 1.40
- Mkt cap
- 5.11M
- Vol
- 0
- Avg vol
- 26.50K
- EPS
- -1.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.28
- Beta
- 0.99
- Short ratio
- 0.75
- Inst. own
- 7.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 4.18
- 200-d avg
- 2.54
- 1y target
- 0.00
News
3 days ago globenewswire.com
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
Interim Results in Super-Aged Rats Tested Externally Show Preserved Motor Performance and Reduced Fat Mass, Consistent with Prior Findings in Aged Mice Tested at Eos's R&D Facility; Data Support…
-
1 week ago benzinga.com
Eos SENOLYTIX Presents New Preclinical Survival, Healthspan, Mechanism-Of-Action Data For Its PTC-2105 Candidate At 17th World Congress On Targeting Mitochondria 2026
Eos SENOLYTIX, Inc. ("Eos" or the "Company") a biotechnology company developing mitochondria-targeted geropeptides to improve healthspan, today presented new preclinical survival, healthspan and
-
1 month ago benzinga.com
Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity
Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and is conducting IND-enabling studies to support the initiation of first-in-human clinical trials,…
-
1 month ago benzinga.com
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4
Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and
-
2 months ago benzinga.com
Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.29) per share. This is a 30.95 percent increase over losses of $(0.42) per share from the same period last year.
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Pulmatrix Q1 EPS $(0.32) Up From $(0.50) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.32) per share. This is a 36 percent increase over losses of $(0.50) per share from the same period last year.
7 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
7 months ago benzinga.com
Pulmatrix Signs Agreement To Acquire Eos SENOLYTIX; Financial Terms Undisclosed
Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc. ("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related…
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
8 months ago benzinga.com
Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.25) per share. This is a 54.55 percent increase over losses of $(0.55) per share from the same period last year.
-
10 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule…
-
1 year ago benzinga.com
Pulmatrix Q3 EPS $(0.24) Up From $(0.71) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.24) per share. This is a 66.2 percent increase over losses of $(0.71) per share from the same period last year.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.
-
1 year ago benzinga.com
Pulmatrix Seeks Divestment Of Clinical Assets And iSPERSE Inhalation Technology Amid Advancements In Migraine, COPD, And Antifungal Treatments
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE™ TechnologyiSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Pulmatrix And Cullgen Announce Proposed Merger; Pre-Merger Pulmatrix Stockholers To Own ~3.6% Of Combined Company; Pre-Merger Cullgen Stockholders To Own ~96.4% Of Combined Company Under Name Cullgen
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials – two for the treatment of…
-
1 year ago benzinga.com
Pulmatrix Q3 EPS $(0.71) Up From $(1.03) YoY, Sales $366.00K Down From $1.75M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.71) per share. This is a 31.07 percent increase over losses of $(1.03) per share from the same period last year. The company reported $366.00…
-
2 years ago benzinga.com
Pulmatrix Announces Peer-Reviewed Publication Headache: The Journal Of Head And Face Pain, Clinical Results For Its Orally Inhaled DHE For Acute Migraine
Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) administered DHE.Self-administered PUR3100 showed…
-
2 years ago benzinga.com
Pulmatrix Q4 EPS $(0.57) Beats $(1.04) Estimate, Sales $2.20M Beat $1.77M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(1.04) by 45.19 percent. This is a 50 percent increase over losses of $(1.14) per…
-
2 years ago benzinga.com
Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives
Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix…
-
2 years ago benzinga.com
Pulmatrix Q3 EPS $(1.03) Beats $(1.05) Estimate, Sales $1.75M Miss $1.86M Estimate
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.03) per share which beat the analyst consensus estimate of $(1.05) by 1.9 percent. This is a 28.97 percent increase over losses of $(1.45) per…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 311 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 386 stocks made new 52-week lows.
-
3 years ago benzinga.com
Pulmatrix Announces FDA Acceptance Of IND Application For PUR3100 To Treat Acute Migraine
Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment of acute migraine
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 225 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 59 companies achieved new lows for the year.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 99 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Pulmatrix Announces Publication On Physiologically Based Pharmacokinetic Modelling Of Potential Drug-Drug Interactions With PUR1900, Orally Inhaled Itraconazole
Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is administered with medications contraindicated with oral itraconazolePulmatrix is currently…
-
3 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
-
3 years ago benzinga.com
Pulmatrix Q2 EPS $(1.04) Up From $(1.36) YoY, Sales $1.84M Up From $1.33M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.04) per share. This is a 23.53 percent increase over losses of $(1.36) per share from the same period last year. The company reported $1.84…
-
3 years ago benzinga.com
Pulmatrix Announces Submission Of IND Application To FDA To Initiate A Phase 2 Trial Of Investigational Drug PUR3100 To Treat Acute Migraine
Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 120 stocks hit new 52-week lows.
-
3 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Pulmatrix, Maintains $10 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Pulmatrix (NASDAQ:PULM) with a Buy and maintains $10 price target.
-
3 years ago benzinga.com
Pulmatrix Q1 EPS $(1.22) Up From $(1.51) YoY, Sales $1.50M Up From $1.16M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.22) per share. This is a 19.21 percent increase over losses of $(1.51) per share from the same period last year. The company reported $1.50…
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 185 companies achieved new lows for the year.
-
3 years ago benzinga.com
Pulmatrix Announces Year-End And Q4 Financial 2022 Results And Provides Corporate Update; $35.6M In Cash And Cash Equivalents At The End Of 2022 Providing Cash Runway Into Q2 2024
PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in cash and cash equivalents at
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 89 stocks made new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 479 stocks made new 52-week lows.
-
4 years ago benzinga.com
93 Biggest Movers From Friday
Gainers Inspirato Incorporated (NASDAQ: ISPO) shares surged 50.5% to close at $54.90.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday morning, 282 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
Monday morning saw 78 companies set new 52-week lows.